Your science is rigorous. 
Your finances should be, too.

Clinical research teams do some of the most consequential work in healthcare.

Every visit, procedure, and result contributes to evidence that could change lives.

But the financial record of that work is scattered across contracts, clinical systems, sponsor portals, and spreadsheets. Teams spend hours determining what they’re owed, following up on invoices, and matching payments to work already completed. Understanding the economics of a study is even harder.

We started Peppermint to bring the discipline of clinical research to the financial operations that fuel it.

Built by operators who understand what it takes to deliver precision at scale.

Our founders, David Freeman and Vijay Thurimella, met at X1 as its first business hire and first engineering hire. Together, they helped build the financial infrastructure behind a consumer credit-card business that ultimately became the Robinhood Gold Card.

That work required an absolutely accurate understanding of what should have happened, what money actually moved, and how to reconcile the difference. Millions of times a day, each transaction had to withstand layers of scrutiny.

Peppermint brings that operating and engineering experience to the complexity of clinical research.

Revenue today. A financial engine for tomorrow.

With an AI-powered financial platform exclusively built for clinical trial sites and systems, we capture earned revenue, create accurate invoices, reconcile payments, and recover money that might otherwise go uncollected.

We work within the systems teams already use, connecting financial activity to the underlying record so they can understand and defend the numbers.

Set up is turnkey. Recovery often begins in the first weeks.

Fixing finance is just the beginning.

When the money is measurable, everyone driving clinical trials benefits: sites can grow, health systems can invest with confidence, and CROs and sponsors can make decisions with clearer financial information.

As scientific discovery accelerates with AI, the capacity to test new therapies must grow with it. We're helping to build a future where clinical research can meet that moment.